Marubi(SH:603983) Orient Securities·2025-08-26 12:42Investment Rating - The report maintains a "Buy" rating for the company with a target price of 43.39 CNY, based on a DCF valuation [2][10]. Core Views - The company has experienced a short-term decline in profitability due to increased marketing expenditures, but the dual-brand strategy is expected to drive future growth [1][9]. - The company’s revenue and profit grew by approximately 31% and 5% respectively in the first half of the year, with a significant 39% increase in sales expenses [9]. - The company is focusing on enhancing its competitiveness in the beauty sector, particularly in eye care, with a 76% year-on-year increase in eye product sales [9]. - The company is expected to see improved profitability in the second half of the year, with a decrease in the sales expense ratio anticipated [9]. Financial Performance Summary - Revenue projections for 2025-2027 are adjusted to 3,802 million CNY, 4,656 million CNY, and 5,582 million CNY respectively, with year-on-year growth rates of 28.0%, 22.5%, and 19.9% [7][10]. - The expected earnings per share for 2025-2027 are 1.07 CNY, 1.44 CNY, and 1.83 CNY respectively [2][10]. - The gross margin is projected to improve from 70.7% in 2023 to 75.2% in 2027, while the net profit margin is expected to increase from 11.7% to 13.1% over the same period [9][14].